Joseph P. Lyssikatos Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $26.70, for a total value of $320,400.00. Following the transaction, the insider now directly owns 1,093,035 shares in the company, valued at approximately $29,184,034.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Enliven Therapeutics Trading Down 6.0 %

Shares of Enliven Therapeutics stock opened at $23.22 on Friday. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67. The company’s fifty day simple moving average is $22.82 and its 200-day simple moving average is $19.56. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -12.03 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently modified their holdings of the company. SG Americas Securities LLC raised its stake in shares of Enliven Therapeutics by 17.8% in the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after purchasing an additional 2,041 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics in the 4th quarter valued at $66,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after buying an additional 1,029 shares in the last quarter. AJOVista LLC acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at $28,000. Finally, EntryPoint Capital LLC bought a new position in shares of Enliven Therapeutics during the 1st quarter worth about $167,000. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ELVN. Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target on the stock. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price for the company.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.